- Home
- GTX vs VRDN Comparison
GTX vs VRDN Comparison
Compare GTX & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTX | VRDN |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GTX | VRDN |
|---|---|---|
| Price | $18.18 | $29.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $20.00 | ★ $41.42 |
| AVG Volume (30 Days) | ★ 2.4M | 1.5M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ 55.30 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $3,537,000,000.00 | $70,789,000.00 |
| Revenue This Year | $3.71 | $26,080.80 |
| Revenue Next Year | $3.41 | $2.07 |
| P/E Ratio | $11.60 | ★ N/A |
| Revenue Growth | N/A | ★ 23340.07 |
| 52 Week Low | $7.02 | $9.90 |
| 52 Week High | $19.28 | $34.29 |
Technical Indicators
Market Signals| Indicator | GTX | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 39.52 |
| Support Level | $18.14 | $29.04 |
| Resistance Level | $18.67 | $34.18 |
| Average True Range (ATR) | 0.48 | 1.40 |
| MACD | -0.04 | -0.46 |
| Stochastic Oscillator | 79.02 | 18.99 |
Price Performance
Historical ComparisonAbout GTX Garrett Motion Inc.
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).